1-[Fluoro(pyrrolidin-1-ium-1-ylidene)methyl]pyrrolidine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 1-[Fluoro(pyrrolidin-1-ium-1-ylidene)methyl]pyrrolidine
• 化学式: C9H16FN2+
• 分子量: 171.24
• InChiKey: JKIZKZLTBZCMSQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  6.2
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• [EN] 1,3-SUBSTITUED PYRAZOLE COMPOUNDS USEFUL FOR REDUCTION OF VERY LONG CHAIN FATTY ACIC LEVELS<br/>[FR] COMPOSÉS PYRAZOLE 1,3-SUBSTITUÉS UTILES POUR LA RÉDUCTION DE NIVEAUX D'ACIDES GRAS À CHAÎNE TRÈS LONGUE
  申请人：VERTEX PHARMA

  公开号：WO2018107056A1

  公开（公告）日：2018-06-14

  Disclosed are chemical entities which are compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein Formula (I) has the structure: R1a, R1b, R2, R3, R4a, R4b and Y are as defined herein. These chemical entities are useful for reduction of very long chain fatty acid levels. These chemical entities and pharmaceutically acceptable compositions comprising such chemical entities can be useful for treating various diseases, disorders and conditions, such as adrenoleukodystrophy (ALD).

  揭示了化学实体，它们是具有式（I）的化合物及其药学上可接受的盐，其中式（I）具有结构：R1a，R1b，R2，R3，R4a，R4b和Y如本文所定义。这些化学实体对于降低非常长链脂肪酸水平是有用的。这些化学实体和包括这些化学实体的药学上可接受的组合物可用于治疗各种疾病、疾病和症状，如肾上腺白质脑白质营养不良（ALD）。
• [EN] BISARYL HETEROCYCLES AS NRF2 ACTI<br/>[FR] HÉTÉROCYCLES BISARYLE EN TANT QUE NRF2 ACTI
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2018109643A1

  公开（公告）日：2018-06-21

  The present invention relates to bisaryl heterocycle compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 activators. In particular, the invention relates to bisaryl heterocycles of Formula (I),

  本发明涉及双芳基杂环化合物，制备方法，包含它们的药物组合物以及它们作为NRF2激活剂的用途。具体而言，该发明涉及式（I）的双芳基杂环化合物。
• [EN] NOVEL COMPOUNDS AND METHODS OF USE TREATING FRUCTOSE-RELATED DISORDERS OR DISEASES<br/>[FR] NOUVEAUX COMPOSÉS ET MÉTHODES D'UTILISATION POUR LE TRAITEMENT DE TROUBLES OU DE MALADIES LIÉS AU FRUCTOSE
  申请人：COLORADO RES PARTNERS LLC

  公开号：WO2020215022A1

  公开（公告）日：2020-10-22

  Disclosed herein are novel compounds that inhibit fructokinase (KHK or ketohexokinase) and the downstream metabolic effects mediated by fructose metabolism. Fructokinase inhibitors specifically block the metabolism of both dietary and endogenous fructose metabolism and have a host of potential metabolic benefits.

  本文披露了一种新型化合物，可以抑制果糖激酶（KHK或酮己糖激酶）以及由果糖代谢介导的下游代谢效应。果糖激酶抑制剂可以特异性地阻断膳食和内源性果糖代谢的代谢，并具有一系列潜在的代谢益处。
• [EN] PROCESSES FOR PREPARING PHARMACEUTICALLY RELEVANT PEPTIDES<br/>[FR] MÉTHODES DE PRÉPARATION DE PEPTIDES PERTINENTS SUR LE PLAN PHARMACEUTIQUE
  申请人：STEALTH BIOTHERAPEUTICS CORP

  公开号：WO2016144905A1

  公开（公告）日：2016-09-15

  The present technology provides methods of generating the peptides, and pharmaceutically acceptable salts of the peptides and intermediates thereof. In some embodiments, the peptide is D-Arg-2´6´-Dmt-Lys-Phe-NH2.

  目前的技术提供了产生肽、肽的药用可接受盐和中间体的方法。在某些实施例中，该肽为D-Arg-2´6´-Dmt-Lys-Phe-NH2。
• METHOD FOR PRODUCING HAIRPIN SINGLE-STRAND RNA MOLECULES
  申请人：Toray Industries, Inc.

  公开号：EP3862431A1

  公开（公告）日：2021-08-11

  The present invention relates to a method for producing a hairpin single-stranded RNA molecule capable of inhibiting expression of a target gene, comprising the step of reacting a first single-stranded oligo-RNA molecule represented by the following formula (I) with a second single-stranded oligo-RNA molecule represented by the following formula (II) in a mixed solvent comprising a buffer solution and a hydrophilic organic solvent in the presence of a dehydration condensation agent: 5'-Xc-Lx1 ... (I) and Lx2-X-Y-Ly-Yc-3' ... (II), wherein the dehydration condensation agent is selected from the group consisting of a triazine-based dehydration condensation agent, a uronium-based dehydration condensation agent comprising an N-hydroxy nitrogen-containing aromatic ring structure, a carbodiimide-based dehydration condensation agent, a 2-halopyridinium-based dehydration condensation agent, and a formamidinium-based dehydration condensation agent.

  本发明涉及一种生产能够抑制靶基因表达的发夹型单链 RNA 分子的方法，包括以下步骤： 在由缓冲溶液和亲水性有机溶剂组成的混合溶剂中，在脱水缩合剂存在的情况下，由下式 (I) 表示的第一单链寡核苷酸分子与由下式 (II) 表示的第二单链寡核苷酸分子反应： 5'-Xc-Lx1 ...... (I) 和 Lx2-X-Y-Ly-Yc-3' ...... (II) ，其中脱水缩合剂选自由三嗪类脱水缩合剂、脲类脱水缩合剂、脲类脱水缩合剂和脲类脱水缩合剂组成的组。...(I)和 Lx2-X-Y-Ly-Yc-3' ...(II)，其中脱水缩合剂选自由三嗪基脱水缩合剂、包含 N-羟基含氮芳香环结构的脲基脱水缩合剂、碳二亚胺基脱水缩合剂、2-卤代吡啶鎓基脱水缩合剂和甲脒基脱水缩合剂组成的组。